Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Find a clinical trial that's recruiting now
Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.
- 24,857
- trials recruiting now
- 14%
- of all US trials open to enrollment
- 52
- states with recruiting sites
A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.
Popular conditions
Showing the 40 largest recruiting trials by target enrollment in Montana. Use the search field to focus on a condition or drug.
RIVER At Home Ketamine Protocols
RIVER Foundation
NCT06070766
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Kailera
NCT07284901
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Kailera
NCT07284979
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Bristol-Myers Squibb
NCT06561386
Abbott Cephea Mitral Valve Disease Registry
Abbott Medical Devices
NCT07069673
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Daiichi Sankyo
NCT06899126
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity
NCT06757634
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology
NCT05254743
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines
NCT06162221
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company
NCT06972472
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Merck Sharp & Dohme
NCT06345729
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Biotest
NCT05722938
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Daiichi Sankyo
NCT06819007
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
GlaxoSmithKline
NCT06679101
Improving Psychological and Vestibular Health: MINDGAPS
University of Montana
NCT05986279
Ketamine Treatment Plans for Chronic Conditions
RIVER Foundation
NCT06038409
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation
NCT07214779
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
NCT06614192
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Revolution Medicines
NCT06881784
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Inhibrx Biosciences
NCT06295731
Trauma and Cardiometabolic Health in an American Indian Community
Montana State University
NCT06878885
LMN-201 for Prevention of C. Difficile Infection Recurrence
Lumen Bioscience
NCT05330182
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme
NCT06797635
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Olatec Therapeutics
NCT05658575
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma
NCT07219602
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
GlaxoSmithKline
NCT05757102
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Merck Sharp & Dohme
NCT05139017
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Hoffmann-La Roche
NCT07112872
Impella RP Flex with Smart Assist
Abiomed
NCT06637644
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00339287
TTVR Early Feasibility Study
Medtronic Cardiovascular
NCT04433065
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
University of Colorado, Denver
NCT07001241
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
Acoustic Wave Cell Therapy
NCT06862648
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06120244
Gut Microbiota-dependent Health Impacts of Haskap Berries
Montana State University
NCT06546020
Contoura With Phorcides Compared to Wavefront Optimized LASIK
Daniel Terveen
NCT05486546
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune
NCT06425926
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Blueprint Medicines Corporation
NCT06931405
Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis
Healeon Medical
NCT04238143
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad
NCT04291105
Read our methodology - how recruiting status is sourced and refreshed from the public registry.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.